What is claimed is:

1. A method for treatment of a human subject with myelofibrosis or a myeloproliferative neoplasm (MPN)-related disorder, comprising

administering a therapeutically effective amount of navitoclax selected from the group consisting of 50 mg, 100 mg, 200 mg, and 300 mg; in combination with

administering a therapeutically effective amount of ruxolitinib;

wherein the treatment of the human subject results in a spleen volume reduction of at least 35%,

wherein the MPN-related disorder is selected from the group consisting of polycythemia vera (PCV), essential thrombocytopenia (ET), and chronic monomyelocytic leukemia (CMML).

2. The method of claim 1, wherein the therapeutically effective amount of ruxolitinib is at least 10 mg.
3. The method of claim 2, wherein the therapeutically effective amount of navitoclax is administered once a day; and wherein the therapeutically effective amount of ruxolitinib is administered twice a day.
4. The method of claim 3, wherein the therapeutically effective amount of navitoclax is 100 mg.
5. The method of claim 3, wherein the therapeutically effective amount of navitoclax is 200 mg.
6. The method of claim 3, wherein the human subject has been treated with a JAK-2 inhibitor prior to administering the therapeutically effective amount of navitoclax.
7. The method of claim 6, wherein the therapeutically effective amount of navitoclax is 100 mg; and wherein the therapeutically effective amount of ruxolitinib is 10 mg.
8. The method of claim 6, wherein the therapeutically effective amount of navitoclax is 200 mg; and wherein the therapeutically effective amount of ruxolitinib is 10 mg.
9. The method of claim 1, wherein the treatment of the human subject results in a spleen volume reduction of at least 35% by week 24.
10. A method for treatment of a human subject with myelofibrosis, comprising

administering a therapeutically effective amount of navitoclax selected from the group consisting of 50 mg, 100 mg, 200 mg, and 300 mg; in combination with

administering a therapeutically effective amount of ruxolitinib;

wherein the myelofibrosis is relapsed or refractory myelofibrosis; and

wherein the treatment of the human subject results a spleen volume reduction of at least 35%.

11. The method of claim 10, wherein the therapeutically effective amount of ruxolitinib is at least 10 mg.
12. The method of claim 11, wherein the therapeutically effective amount of navitoclax is administered once a day; and wherein the therapeutically effective amount of ruxolitinib is administered twice a day.
13. The method of claim 12, wherein the therapeutically effective amount of navitoclax is 100 mg.
14. The method of claim 12, wherein the therapeutically effective amount of navitoclax is 200 mg.
15. The method of claim 10, wherein the human subject has received at least one dose of ruxolitinib prior to administering a therapeutically effective amount of navitoclax.
16. The method of claim 15, wherein the human subject has received a dose of at least 10 mg ruxolitinib twice a day for 12 weeks prior to administering a therapeutically effective amount of navitoclax.
17. The method of claim 16, wherein the therapeutically effective amount of navitoclax is 100 mg.
18. The method of claim 16, wherein the therapeutically effective amount of navitoclax is 200 mg.
19. A method for treatment of a human subject with myelofibrosis, comprising

administering a therapeutically effective amount of navitoclax selected from the group consisting of 50 mg, 100 mg, 200 mg, and 300 mg; in combination with

administering a therapeutically effective amount of ruxolitinib;

wherein the myelofibrosis is relapsed or refractory myelofibrosis; and

wherein treatment of the human subject results in an improvement in a grade of bone marrow fibrosis relative to a baseline grade of bone marrow fibrosis.

20. The method of claim 19, wherein the therapeutically effective amount of ruxolitinib is at least 10 mg.
21. The method of claim 20, and wherein the therapeutically effective amount of navitoclax is administered once a day; and wherein the ruxolitinib dose is administered twice a day.

22. The method of claim 21, wherein the therapeutically effective amount of navitoclax is 100 mg.
23. The method of claim 21, wherein the therapeutically effective amount of navitoclax is 200 mg.
24. The method of claim 1, wherein the human subject has failed to achieve a spleen volume reduction of at least 35% prior to being administered navitoclax.
25. The method of claim 1, wherein an initial dose of therapeutically effective amount of navitoclax is 50 mg; and

Wherein after at least 7 days the therapeutically effective amount of navitoclax is increased to a next higher dose of the therapeutically effective amount of navitoclax.
26. The method of claim 1, wherein the human subject has received at least one dose of ruxolitinib of more than 10 mg prior to administering the therapeutically effective amount of navitoclax;

wherein the dose of ruxolitinib is reduced to the therapeutically effective amount of ruxolitinib of 10 mg after administering the therapeutically effective amount of navitoclax.
27. A method for significantly reducing spleen volume in a human subject with myelofibrosis who is refractory to treatment with a JAK-2 inhibitor, comprising

orally administering to the human subject with myelofibrosis once a day a therapeutically effective amount of navitoclax selected from the group consisting of 50 mg, 100 mg, 200 mg, and 300 mg; in combination with

orally administering to the human subject with myelofibrosis twice a day a therapeutically effective amount of ruxolitinib;

wherein following 24 weeks of said administering navitoclax in combination with ruxolitinib, the spleen volume of the human subject with myelofibrosis is reduced by at least 35%.
28. A method for improving bone marrow fibrosis grade in a human subject with myelofibrosis who is refractory to treatment with a JAK-2 inhibitor, comprising

orally administering to the human subject with myelofibrosis once a day a therapeutically effective amount of navitoclax selected from the group consisting of 50 mg, 100 mg, 200 mg, and 300 mg; in combination with

orally administering to the human subject with myelofibrosis twice a day a therapeutically effective amount of ruxolitinib;

wherein following 24 weeks of said administering navitoclax in combination with ruxolitinib the bone marrow fibrosis grade of the human subject with myelofibrosis is improved by at least one grade.

29. A method for treatment of myelofibrosis in a human subject in need thereof, comprising orally administering to said subject an effective amount of navitoclax in combination with an effective amount of ruxolitinib, wherein

(i) if the human subject has a baseline platelet count of greater than or equal to 150 x 10^9/L, the effective amount of navitoclax comprises 200 mg once daily, and if the human subject has a baseline platelet count of less than 150 x 10^9/L, the effective amount of navitoclax comprises 100 mg once daily, escalated to 200 mg once daily after 7 days or more if the human subject has a platelet count greater than or equal to 75 x 10^9/L, and

(ii) the effective amount of ruxolitinib comprises 10 mg twice daily;

wherein the effective amount of navitoclax is optionally increased to 300 mg once daily if the human subject fails to achieve spleen reduction volume of at least 35% (SVR_{35}) by week 24 of treatment.

30. The method of claim 29, wherein the myelofibrosis comprises relapsed/refractory (R/R), intermediate or high-risk primary or secondary myelofibrosis, post-polycythemia vera or post-essential thrombocytopenia myelofibrosis.

31. The method of claim 29, wherein the effective amount of navitoclax is optionally modified or interrupted due to thrombocytopenia or neutropenia.

32. The method of claim 31, wherein

(i) if the subject has a platelet count between 75 x 10^9/L and greater than or equal to 50 x 10^9/L the effective amount of navitoclax is optionally reduced;

(ii) if the subject has a platelet count less than 50 x 10^9/L, the navitoclax is interrupted or discontinued until platelets levels stabilize above a level greater than or equal to 50 x 10^9/L;

(iii) if the subject has an absolute neutrophil count (ANC) less than 1.0 but greater than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L; and

(iv) if the subject has an absolute neutrophil count (ANC) less than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L and navitoclax is interrupted or discontinued until ANC is greater than 1.0 x 10^9/L.

33. The method of claim 29, wherein the effective amount of ruxolitinib is modified or interrupted due to thrombocytopenia.

34. A method for treatment of myelofibrosis in a human subject in need thereof, comprising orally administering to said subject an effective amount of navitoclax in combination with an effective amount of ruxolitinib, wherein

(i) if the human subject has a baseline platelet count of greater than or equal to 150 x 10^9/L, the effective amount of navitoclax comprises 200 mg once daily, and if the human subject has a baseline platelet count of less than 150 x 10^9/L, the effective amount of navitoclax comprises 100 mg once daily, escalated to 200 mg once daily after 7 days or more if the human subject has a platelet count greater than or equal to 75 x 10^9/L, and

(ii) if the human subject has a baseline platelet count of greater than 200 x 10^9/L, the effective amount of ruxolitinib comprises 20 mg twice daily, if the subject has a baseline platelet count between 100 x 10^9/L and 200 x 10^9/L, the effective amount of ruxolitinib comprises 15 mg twice daily, and if the subject has a baseline platelet count between 50 x 10^9/L to less than 100 x 10^9/L, the effective amount of ruxolitinib comprises 5 mg twice daily;

wherein the effective amount of navitoclax is optionally increased to 300 mg once daily if the human subject fails to achieve spleen reduction volume of at least 35% (SVR_{35}) by week 24 of treatment.

35. The method of claim 34, wherein the myelofibrosis comprises relapsed/refractory (R/R), intermediate or high-risk primary or secondary myelofibrosis, post-polycythemia vera or post-essential thrombocytopenia myelofibrosis.

36. The method of claim 34, wherein the effective amount of navitoclax is optionally modified or interrupted due to thrombocytopenia or neutropenia.

37. The method of claim 36, wherein

(i) if the subject has a platelet count between 75 x 10^9/L and greater than or equal to 50 x 10^9/L the effective amount of navitoclax is optionally reduced;

(ii) if the subject has a platelet count less than 50 x 10^9/L, the navitoclax is interrupted or discontinued until platelets levels stabilize above a level greater than or equal to 50 x 10^9/L;

(iii) if the subject has an absolute neutrophil count (ANC) less than 1.0 but greater than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L; and

(iv) if the subject has an absolute neutrophil count (ANC) less than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L and navitoclax is interrupted or discontinued until ANC is greater than 1.0 x 10^9/L.

38. The method of claim 34, wherein the effective amount of ruxolitinib is modified or interrupted due to thrombocytopenia.

39. A method for treatment of myelofibrosis in a human subject in need thereof, comprising

(a) obtaining a baseline platelet count from said human subject; and

(b) orally administering to said subject an effective amount of navitoclax in combination with an effective amount of ruxolitinib, wherein

(i) if the human subject has a baseline platelet count of greater than or equal to 150 x 10^9/L, the effective amount of navitoclax comprises 200 mg once daily, and if the human subject has a baseline platelet count of less than 150 x 10^9/L, the effective amount of navitoclax comprises 100 mg once daily, escalated to 200 mg once daily after 7 days or more if the human subject has a platelet count greater than or equal to 75 x 10^9/L, and

(ii) the effective amount of ruxolitinib comprises 10 mg twice daily;

wherein the effective amount of navitoclax is optionally increased to 300 mg once daily if the human subject fails to achieve spleen reduction volume of at least 35% (SVR_{35}) by week 24 of treatment.

40. The method of claim 39, wherein the myelofibrosis comprises relapsed/refractory (R/R), intermediate or high-risk primary or secondary myelofibrosis, post-polycythemia vera or post-essential thrombocytopenia myelofibrosis.

41. The method of claim 39, wherein the effective amount of navitoclax is optionally modified or interrupted due to thrombocytopenia or neutropenia.

42. The method of claim 41, wherein

(i) if the subject has a platelet count between 75 x 10^9/L and greater than or equal to 50 x 10^9/L the effective amount of navitoclax is optionally reduced;

(ii) if the subject has a platelet count less than 50 x 10^9/L, the navitoclax is interrupted or discontinued until platelets levels stabilize above a level greater than or equal to 50 x 10^9/L;

(iii) if the subject has an absolute neutrophil count (ANC) less than 1.0 but greater than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L; and

(iv) if the subject has an absolute neutrophil count (ANC) less than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L and navitoclax is interrupted or discontinued until ANC is greater than 1.0 x 10^9/L.

43. The method of claim 39, wherein the effective amount of ruxolitinib is modified or interrupted due to thrombocytopenia.

44. A method for treatment of myelofibrosis in a human subject in need thereof, comprising

(a) obtaining a baseline platelet count from said human subject; and

(b) orally administering to said subject an effective amount of navitoclax in combination with an effective amount of ruxolitinib, wherein

(i) if the human subject has a baseline platelet count of greater than or equal to 150 x 10^9/L, the effective amount of navitoclax comprises 200 mg once daily, and if the human subject has a baseline platelet count of less than 150 x 10^9/L, the effective amount of navitoclax comprises 100 mg once daily, escalated to 200 mg once daily after 7 days or more if the human subject has a platelet count greater than or equal to 75 x 10^9/L, and

(ii) if the human subject has a baseline platelet count of greater than 200 x 10^9/L, the effective amount of ruxolitinib comprises 20 mg twice daily, if the subject has a baseline platelet count between 100 x 10^9/L and 200 x 10^9/L, the effective amount of ruxolitinib comprises 15 mg twice daily, and if the subject has a baseline platelet count between 50 x 10^9/L to less than 100 x 10^9/L, the effective amount of ruxolitinib comprises 5 mg twice daily;

wherein the effective amount of navitoclax is optionally increased to 300 mg once daily if the human subject fails to achieve spleen reduction volume of at least 35% (SVR_{35}) by week 24 of treatment.

45. The method of claim 44, wherein the myelofibrosis comprises relapsed/refractory (R/R), intermediate or high-risk primary or secondary myelofibrosis, post-polycythemia vera or post-essential thrombocytopenia myelofibrosis.

46. The method of claim 44, wherein the effective amount of navitoclax is optionally modified or interrupted due to thrombocytopenia or neutropenia.

47. The method of claim 46, wherein

(i) if the subject has a platelet count between 75 x 10^9/L and greater than or equal to 50 x 10^9/L the effective amount of navitoclax is optionally reduced;

(ii) if the subject has a platelet count less than 50 x 10^9/L, the navitoclax is interrupted or discontinued until platelets levels stabilize above a level greater than or equal to 50 x 10^9/L;

(iii) if the subject has an absolute neutrophil count (ANC) less than 1.0 but greater than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L; and

(iv) if the subject has an absolute neutrophil count (ANC) less than 0.5 x 10^9/L, the subject is optionally supported with G-CSF or antibiotics until ANC is greater than 1.0 x 10^9/L and navitoclax is interrupted or discontinued until ANC is greater than 1.0 x 10^9/L.

48. The method of claim 44, wherein the effective amount of ruxolitinib is modified or interrupted due to thrombocytopenia.